Compared to its homolog, CDK4 favors mesenchymal tissues (including leukemias and sarcomas), and epithelial tumours (i.e., various malignancies), and some sarcomas tend to express more CDK4 [54]. This evidence concerns the gene CDK4 and sarcoma.